Physician Underutilization of Effective Medications for Resistant Hypertension at Office Visits in the United States: NAMCS 2006–2010
Open Access
- 19 November 2013
- journal article
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 29 (3) , 468-476
Abstract
The American Heart Association (AHA) published guidelines for treatment of resistant hypertension in 2008 recommending use of thiazide diuretics (particularly chlorthalidone), aldosterone antagonists, and fixed-dose combination medications, but it is unclear the extent to which these guidelines are being followed. To describe trends in physician use of recommended medications for resistant hypertension and assess variations in medication use based on geography, physician specialty and patient characteristics. Cross-sectional analysis using the National Ambulatory Medical Care Survey from 2006 to 2010. We analyzed visits of hypertension patients to family physicians, general internists, and cardiologists. Resistant hypertension was defined as concurrent use of ≥ 4 classes of blood pressure (BP) medications or elevated BP despite the use of ≥ 3 medications. Pregnant patients and visits with diagnosed heart failure or end-stage renal disease were excluded. Use of AHA-recommended medications for management of resistant hypertension. Of 19,500 patient visits with hypertension, 1,567 or 7.1 % CI (6.6–7.7 %) met criteria for resistant hypertension. Thiazide diuretic use was reported in 58.9 % of visits pre-guidelines vs. 54.8 % post-guidelines (p = 0.37). Use of aldosterone antagonists was low and also did not change significantly after guideline publication (3.1 % vs. 4.5 %, p = 0.27). Fixed-dose combinations use was 42.0 % before and 37 % after guideline publication (p = 0.29). Each 10-year increase in patient age was associated with lower thiazide use (OR 0.87, CI 0.77–0.97), as was presence of comorbid ischemic heart disease (OR 0.62, CI 0.41–0.94). Medication use did not vary by geography or physician specialty. Use of AHA-recommended medications for resistant hypertension remains low after publication of guidelines. Healthcare systems should encourage more frequent prescribing of these medications to improve care in this high-risk population.Keywords
This publication has 36 references indexed in Scilit:
- Effect of intensive structured care on individual blood pressure targets in primary care: multicentre randomised controlled trialBMJ, 2012
- Resistant HypertensionCirculation, 2012
- Incidence and Prognosis of Resistant Hypertension in Hypertensive PatientsCirculation, 2012
- Current challenges in the clinical management of hypertensionNature Reviews Cardiology, 2011
- Uncontrolled and Apparent Treatment Resistant Hypertension in the United States, 1988 to 2008Circulation, 2011
- Diagnosis and management of patients with white-coat and masked hypertensionNature Reviews Cardiology, 2011
- Aldosterone Blockers (Mineralocorticoid Receptor Antagonism) and Potassium-Sparing DiureticsThe Journal of Clinical Hypertension, 2011
- Interventions used to improve control of blood pressure in patients with hypertensionCochrane Database of Systematic Reviews, 2010
- Toward Evidence-Based Quality Improvement.Journal of General Internal Medicine, 2006
- The underutilization of cardiacmedications of proven benefit, 1990 to 2002JACC, 2003